Janssen Argues Patents Over Schizophrenia Drug Are Novel
Janssen has denied a rival's claim that the court should revoke its two patents covering how an injectable form of schizophrenia medication should be given to patients who miss a dose,...To view the full article, register now.
Already a subscriber? Click here to view full article